HomeInsightsStock Comparison

Fdc Ltd vs Shilpa Medicare Ltd Stock Comparison

Fdc Ltd vs Shilpa Medicare Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of FDC Ltd is ₹ 456.5 as of 21 May 10:09.
  • The P/E Ratio of FDC Ltd changed from 14 on March 2020 to 22.6 on March 2024 . This represents a CAGR of 10.05% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 12.8 on March 2020 to 125.7 on March 2024 . This represents a CAGR of 57.92% over 5 years.
  • The Market Cap of FDC Ltd changed from ₹ 3350 crore on March 2020 to ₹ 6912 crore on March 2024 . This represents a CAGR of 15.59% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 1993 crore on March 2020 to ₹ 4004 crore on March 2024 . This represents a CAGR of 14.97% over 5 years.
  • The revenue of FDC Ltd for the Dec '24 is ₹ 482.94 crore as compare to the Sep '24 revenue of ₹ 548.55 crore. This represent the decline of -11.96% The revenue of Shilpa Medicare Ltd for the Dec '24 is ₹ 320.79 crore as compare to the Sep '24 revenue of ₹ 348.79 crore. This represent the decline of -8.03%.
  • The ebitda of FDC Ltd for the Dec '24 is ₹ 65.48 crore as compare to the Sep '24 ebitda of ₹ 104.86 crore. This represent the decline of -37.55% The ebitda of Shilpa Medicare Ltd for the Dec '24 is ₹ 82.17 crore as compare to the Sep '24 ebitda of ₹ 90.61 crore. This represent the decline of -9.31%.
  • The net profit of FDC Ltd changed from ₹ 109.81 crore to ₹ 37.04 crore over 7 quarters. This represents a CAGR of -46.26% The net profit of Shilpa Medicare Ltd changed from ₹ 1.18 crore to ₹ 31.78 crore over 7 quarters. This represents a CAGR of 556.60% .
  • The Dividend Payout of FDC Ltd changed from 5.54 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.63 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About FDC Ltd

  • FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
  • The Company is a prominent player in the Indian pharmaceutical industry, renowned for its expertise in developing specialised formulations.
  • It leads the market in sectors such as Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies.
  • It has established a global footprint in both domestic and international market, standing as a beacon of excellence in pharmaceutical and consumer healthcare industry. Promoted as a partnership firm in 1936 by the Late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods, FDC Limited was established on September 23, 1940.

About Shilpa Medicare Ltd

  • Shilpa Medicare Limited (Formerly known as Shilpa Antibiotics Private Limited) was incorporated as a Private Limited Company on November 20, 1987.
  • The Company changed the status to Public Limited and the name of the Company was changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
  • The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
  • It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.

FDC Ltd News Hub

News

FDC to declare Quarterly Results

FDC will hold a meeting of the Board of Directors of the Company on 12 February 2025. Powe...

Read more

08 Feb 2025 11:03

News

FDC gets USFDA nod for anti-bacterial drug

The announcement was made at the fag end of market hours yesterday. Cefixime is used to tr...

Read more

19 Dec 2024 10:47

News

Board of FDC recommends first interim dividend

FDC announced that the Board of Directors of the Company at its meeting held on 6 November...

Read more

07 Nov 2024 15:15

News

FDC schedules board meeting

FDC will hold a meeting of the Board of Directors of the Company on 6 November 2024 Powere...

Read more

29 Oct 2024 15:20

News

FDC Ltd leads gainers in 'A' group

Kaynes Technology India Ltd, Engineers India Ltd, Mrs Bectors Food Specialities Ltd and Va...

Read more

12 Sep 2024 12:00

News

FDC schedules AGM

FDC announced that the Annual General Meeting (AGM) of the company will be held on 26 Sept...

Read more

10 Sep 2024 10:33

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare to conduct board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 26 May 202...

Read more

19 May 2025 16:26

News

Shilpa Medicare gains after arm receives EIR from USFDA for unit-1 facility

In an exchange filing, the company stated that the USFDA has classified the inspection out...

Read more

15 May 2025 09:56

News

Shilpa Medicare receives USFDA approval for Varenicline tablets

Varenicline helps people quit smoking by blocking the effect of nicotine on the brain. Nic...

Read more

09 Apr 2025 14:40

News

Shilpa Medicare receives USFDA approval for Varenicline Tablets

Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg. Th...

Read more

09 Apr 2025 15:25

News

Shilpa Medicare rallies on BORUZU injections launch in US

BORUZU (Bortezomib for injection 3.5mg/1.4ml) is a proteasome inhibitor used for the treat...

Read more

03 Apr 2025 14:38

News

Shilpa Medicare zooms as arm partners with mAbTree Biologics for cancer drug

Under the terms of the strategic agreement, Shilpa Biologicals will support both developme...

Read more

18 Mar 2025 11:11

SWOT Analysis Of FDC Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Shilpa Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for FDC Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Shilpa Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of FDC Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, FDC Ltd or Shilpa Medicare Ltd?

Market cap of FDC Ltd is 7,431 Cr while Market cap of Shilpa Medicare Ltd is 6,887 Cr

What are the key factors driving the stock performance of FDC Ltd and Shilpa Medicare Ltd?

The stock performance of FDC Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for FDC Ltd and Shilpa Medicare Ltd?

As of May 21, 2025, the FDC Ltd stock price is INR ₹456.45. On the other hand, Shilpa Medicare Ltd stock price is INR ₹704.3.

How do dividend payouts of FDC Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of FDC Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions